ASCO: Antibody Boosts Chemo in CLL

CHICAGO (MedPage Today) -- Adding obinutuzumab to standard chemotherapy improves outcomes for older, sicker patients with chronic lymphocytic leukemia, possibly more than adding rituximab, a pivotal trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/06/asco-antibody-boosts-chemo-in-cll.html